PHILADELPHIA,
Dec. 21,
2023 /PRNewswire/ -- Carisma Therapeutics Inc.
(Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage
biopharmaceutical company focused on discovering and developing
innovative immunotherapies, today announced that the company will
present at the 42nd Annual J.P. Morgan Healthcare
Conference on Thursday, January 11,
2024. Steven Kelly, President
and Chief Executive Officer, will make a formal presentation and
answer questions about the company at 11:15
a.m. PST.
Live webcasts will be available on the
Company's Investor Events webpage. A replay of the webcasts
will be archived at the Company's past events section of the
Investor Relations webpage for a limited time following the
event.
About Carisma
Carisma Therapeutics Inc. is a clinical stage
biopharmaceutical company focused on utilizing our proprietary
macrophage and monocyte cell engineering platform to develop
transformative immunotherapies to treat cancer and other serious
diseases. We have created a comprehensive, differentiated
proprietary cell therapy platform focused on engineered macrophages
and monocytes, cells that play a crucial role in both the innate
and adaptive immune response. Carisma is headquartered in
Philadelphia, PA. For more
information, please visit www.carismatx.com.
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302020575.html
SOURCE Carisma Therapeutics Inc.